CEO AUMMIS (The Collider Programme)

CEO AUMMIS (The Collider Programme) AUMMIS | Stem-free Uterine Manipulator for Minimally Invasive Surgery CEO & Co-Founder Opportunity | MedTech | Gynecologic Oncology Laparoscopic hysterectomy depends on a uterine manipulator, and almost every model on the market works by inserting a rigid stem into the uterus. Clinical evidence has linked these manipulators to a higher risk of cancer recurrence , because the stem damages tissue, manipulates the tumor and can spread malignant cells. As a result, many oncology patients still undergo open surgery. AUMMIS removes the stem. Its vacuum-assisted system holds the cervix with interchangeable cups, so surgeons can mobilize the uterus in laparoscopic and robotic surgery without traumatizing tissue or touching the tumor. The project was born at FISABIO and Universitat Jaume I , and is now looking for the CEO who will turn it into a company. Where AUMMIS stands today Functional prototype , with proof of concept completed on cadaveric bodies ( TRL 4 ) Granted Spanish patent , with EPO and US applications pending and freedom to operate confirmed in Europe and the US Classified as a Class IIa medical device ~1.3 million hysterectomies performed worldwide every year A market dominated by large surgical device players whose manipulators are mostly stem-based, a clear path to licensing or strategic partnership A defined roadmap to CE marking , with pilot clinical studies planned for 2027 and a financial strategy combining non-dilutive fun